CA2787173C - Methods and compositions for improved nerve conduction velocity - Google Patents

Methods and compositions for improved nerve conduction velocity Download PDF

Info

Publication number
CA2787173C
CA2787173C CA2787173A CA2787173A CA2787173C CA 2787173 C CA2787173 C CA 2787173C CA 2787173 A CA2787173 A CA 2787173A CA 2787173 A CA2787173 A CA 2787173A CA 2787173 C CA2787173 C CA 2787173C
Authority
CA
Canada
Prior art keywords
group
hydrogen
alkyl
phenyl
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2787173A
Other languages
English (en)
French (fr)
Other versions
CA2787173A1 (en
Inventor
Thomas David Mccarthy
Andrew Rainsford Baker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CA2787173A1 publication Critical patent/CA2787173A1/en
Application granted granted Critical
Publication of CA2787173C publication Critical patent/CA2787173C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2787173A 2010-01-19 2011-01-19 Methods and compositions for improved nerve conduction velocity Expired - Fee Related CA2787173C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29637510P 2010-01-19 2010-01-19
US61/296,375 2010-01-19
PCT/AU2011/000051 WO2011088504A1 (en) 2010-01-19 2011-01-19 Methods and compositions for improved nerve conduction velocity

Publications (2)

Publication Number Publication Date
CA2787173A1 CA2787173A1 (en) 2011-07-28
CA2787173C true CA2787173C (en) 2018-05-01

Family

ID=44306296

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2787173A Expired - Fee Related CA2787173C (en) 2010-01-19 2011-01-19 Methods and compositions for improved nerve conduction velocity

Country Status (10)

Country Link
US (1) US9095587B2 (cg-RX-API-DMAC7.html)
EP (1) EP2525795B1 (cg-RX-API-DMAC7.html)
JP (2) JP6232184B2 (cg-RX-API-DMAC7.html)
CN (2) CN102821765A (cg-RX-API-DMAC7.html)
AU (1) AU2011207104C1 (cg-RX-API-DMAC7.html)
CA (1) CA2787173C (cg-RX-API-DMAC7.html)
ES (1) ES2560327T3 (cg-RX-API-DMAC7.html)
NZ (1) NZ601383A (cg-RX-API-DMAC7.html)
WO (1) WO2011088504A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201205375B (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ605444A (en) * 2010-07-21 2015-06-26 Spinifex Pharm Pty Ltd Salt and solvates of a tetrahydroisoquinoline derivative
US10391331B2 (en) * 2011-03-29 2019-08-27 Biolyst, Llc. Systems and methods for use in treating sensory impairment
JP6232384B2 (ja) 2012-01-06 2017-11-15 ノバルティス アーゲー 複素環式化合物およびその使用方法
JP6258867B2 (ja) 2012-01-25 2018-01-10 ノバルティス アーゲー 複素環式化合物およびその使用方法
EP2807171B1 (en) * 2012-01-25 2020-08-12 Novartis AG Heterocyclic compounds and methods for their use
NZ630908A (en) * 2013-07-08 2017-08-25 Novartis Ag Heterocyclic compounds and methods of their use
CN107001337B (zh) 2015-01-13 2021-05-04 诺华股份有限公司 作为血管紧张素ii型拮抗剂的吡咯烷衍生物
ES2898635T3 (es) 2015-03-12 2022-03-08 Novartis Ag Compuestos heterocíclicos y métodos para su uso
CN106478502B (zh) * 2015-08-29 2021-04-27 上海翰森生物医药科技有限公司 1,2,3,4-四氢异喹啉衍生物、其制备方法和应用
KR102132761B1 (ko) * 2017-06-09 2020-07-17 산동 단홍 파머수티컬 컴퍼니., 리미티드. At2r 수용체 길항제로서의 카르복시산 유도체
CN112585120B (zh) * 2018-11-02 2022-11-11 山东丹红制药有限公司 一种血管紧张素ii受体2拮抗剂的盐型、晶型及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5091390A (en) * 1990-09-20 1992-02-25 E. I. Du Pont De Nemours And Company Treatment of CNS disorders with 4,5,6,7-tetrahydro-1H-imidazo (4,5-)-pyridines and analogs
HUT71331A (en) * 1992-04-13 1995-11-28 Zeneca Ltd Angiotensin ii antagonists against disorders associated with impaired neuronal conduction velocity, especially diabetic neuropathy
US5246943A (en) 1992-05-19 1993-09-21 Warner-Lambert Company Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties
US5236934A (en) 1992-08-26 1993-08-17 E. I. Du Pont De Nemours And Company 1,2,3,4-tetrahydroisoquinolines useful in the treatment of CNS disorders
GB2337701A (en) * 1998-05-26 1999-12-01 United Medical And Dental Schools Of Guys St Thomas Hospitals Treatment of ischemia with an angiotensin II antagonist
NZ555334A (en) * 2004-12-24 2010-05-28 Spinifex Pharm Pty Ltd Method of treatment or prophylaxis of a neuropathic condition using AT2 receptor antagonist
JP5230595B2 (ja) * 2006-03-20 2013-07-10 スピニフェクス ファーマシューティカルズ ピーティーワイ リミテッド 炎症性疼痛の治療または予防の方法
US7828840B2 (en) 2007-11-15 2010-11-09 Med Institute, Inc. Medical devices and methods for local delivery of angiotensin II type 2 receptor antagonists

Also Published As

Publication number Publication date
EP2525795B1 (en) 2015-10-21
JP2013517300A (ja) 2013-05-16
WO2011088504A1 (en) 2011-07-28
JP2016155846A (ja) 2016-09-01
CA2787173A1 (en) 2011-07-28
EP2525795A4 (en) 2013-07-24
ZA201205375B (en) 2013-09-25
AU2011207104C1 (en) 2015-10-08
CN102821765A (zh) 2012-12-12
HK1176554A1 (en) 2013-08-02
AU2011207104A1 (en) 2012-07-26
JP6232184B2 (ja) 2017-11-15
CN107744519A (zh) 2018-03-02
ES2560327T3 (es) 2016-02-18
EP2525795A1 (en) 2012-11-28
NZ601383A (en) 2014-07-25
US9095587B2 (en) 2015-08-04
US20130131103A1 (en) 2013-05-23
AU2011207104B2 (en) 2015-07-02

Similar Documents

Publication Publication Date Title
EP2525795B1 (en) Methods and compositions for improved nerve conduction velocity
EP2156833B1 (en) Prophylactic or therapeutic agent for posterior ocular disease comprising non-ergot selective d2 receptor agonist as active ingredient
Kudo et al. Anesthetic effects on susceptibility to cortical spreading depression
WO1992014453A1 (en) Compositions and methods of treatment of sympathetically maintained pain
RU2012117563A (ru) Режим дозирования модулятора рецептора s1p
PT1830869E (pt) Método de tratamento ou profilaxia
JP6599447B2 (ja) プラダー・ウィリー症候群を治療する方法
US6218411B1 (en) Therapeutics for diabetic complications
KR20130083895A (ko) 2형 당뇨병의 치료
KR20210125507A (ko) 수면성 무호흡의 치료 방법 및 조성물
EP2614821B1 (en) Pharmaceutical composition for treating anxiety disorder, containing n-acetyl-l-cysteine or derivative thereof
US20060167026A1 (en) Antipsychotic molecular-targeting epithelial growth factor receptor
US20210322510A1 (en) Oxytocin improves treatment of obstructive sleep apnea
CN101636391B (zh) 神经病理性疼痛的预防剂和/或治疗剂
HK1176554B (en) Methods and compositions for improved nerve conduction velocity
KR20200135814A (ko) 신규 중추-작용성 그렐린 효능제 및 그의 의학적 용도
KR20260055518A (ko) 포르피린증의 예방 또는 치료제
WO2016028985A2 (en) Method for treating hyperhidrosis
Corletto et al. Pharmacological treatment of pain
KR102952931B1 (ko) 포르피린증의 예방 또는 치료제
JP5714572B2 (ja) 精神障害およびその症状の治療のためのkcnqカリウムチャネル活性の調節方法
WO2014080162A1 (en) Vip and an alpha-adrenergic blocker for use in the diagnosis of erectile dysfunction and vascular ischaemia

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20151201

MKLA Lapsed

Effective date: 20210119